Phathom Pharmaceuticals: FDA Opens Comment Docket on VOQUEZNA Exclusivity Challenge

What happened

Phathom Pharmaceuticals said the FDA opened a public docket on legal and regulatory questions about a challenge to VOQUEZNA's exclusivity through May 3, 2032. Comments are due November 23, 2026, and Phathom will submit comments supporting the FDA's exclusivity decision.

Confirmed

Global impact / market context

Exclusivity means only Phathom can sell VOQUEZNA without generic competition until May 3, 2032. If that protection holds, revenue and cash available stay with Phathom; if it breaks, cheaper copies could cut profit per sale and capital spending plans.

Analyst inference

BDR is suing over the FDA's rejection of its ANDA, a generic drug application referencing VOQUEZNA tablets. Saba says it has a related case and wants to combine it with BDR's. The docket invites public input before the agency's position is tested.

Analyst inference

What to watch

1. Comments are due November 23, 2026, and Phathom said it will submit comments supporting the FDA's exclusivity decision for VOQUEZNA through May 3, 2032. Confirmed
2. Saba says it intends to seek consolidation of its pending case with BDR's litigation over the FDA's rejection of BDR's ANDA referencing VOQUEZNA. Proposed
3. Watch whether the FDA keeps or reopens its exclusivity decision, because that outcome shapes when generic copies can enter and how long Phathom keeps revenue. Analyst inference

Evidence

• Original source link unavailable